TransMedics Group, Inc. (TMDX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 20/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 23.85% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings
- TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds
- TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
- Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
- TransMedics to Present at Upcoming September Investor Conferences
- TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
- TransMedics (TMDX) Q2 2026 Earnings Call Transcript
- TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for TransMedics Group, Inc..
Full TMDX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.